Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 1/2 1Phase 1 1

Status

Completed 6Active not recruiting 1

Sponsor Class

INDUSTRY 6OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 3Sarcoma 2Tumor-Agnostic 1Gastrointestinal 1

Conditions

Carcinoma, Basal Cell 3Basal Cell Nevus Syndrome 2Pancreatic Neoplasms 1Neoplasms 1Chondrosarcoma 1Bone Neoplasms 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × INDUSTRY × IPI-926 × Clear all
NCT02762084 2020-07-23

Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients

PellePharm, Inc.

Phase 2 Completed
17 enrolled 22 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT02828111 2019-01-08

BCC

PellePharm, Inc.

Phase 2 Completed
36 enrolled 17 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT01130142 2017-03-06

A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer

Infinity Pharmaceuticals, Inc.

Phase 1/2 Completed
122 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT01310816 2013-12-05

A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

Infinity Pharmaceuticals, Inc.

Phase 2 Completed
105 enrolled
Sarcoma

Bone Neoplasms

NCT01609179 2012-11-14

IPI-926 Extension Protocol for Continuation of Treatment With IPI-926

Infinity Pharmaceuticals, Inc.

Phase NA Completed
9 enrolled
DermatologicSarcoma

Carcinoma, Basal Cell, Chondrosarcoma

NCT00761696 2012-06-21

A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

Infinity Pharmaceuticals, Inc.

Phase 1 Completed
94 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡